To assess the pathogenicity of genetic variants in patients, we use a rules-based, weighted process (published by our group in 2015) that is aligned with the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) guidelines. We stay current with medical science by attending conferences, presenting research, and sustaining collaborations, such as participation in ClinGen Working Groups and partnerships with academia. We strive to provide the best service for our customers by staying up to date with relevant literature and diagnostic tools. Variant IQ TM and Athena Insight™, Variant IQ’s Neurology Division, are a team of highly specialized and rigorously trained scientists and genetic counselors, whose primary focus is to assess the pathogenicity of genetic variants identified in patients. The Team: Variant IQ TM and Athena Insight TM We look for color in a world of gray results. Our high-touch approach optimizes the value of modern science and human insight. We understand your goals, and we work with you. That’s why we’ve developed a team and a process for determining the significance of genetic variants. When it comes to a genetic diagnosis, you want the most reliable, up-to-date, understandable information. The questions patients ask: What’s causing my symptoms? Why did this happen to me? What are the chances that I might pass this onto my children? The answers aren’t always clear. Variant Investigation by Quest (Variant IQ TM): Finding Color in a World of Gray Results
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |